The Company was established based on the unmet medical needs and driven by technological innovation. The Company focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, nano-delivery carrier technology, prodrug modification, and solubility enhancement technology for insoluble drugs. The Company puts a lot of emphasis on patent protection throughout the full life cycle of drug development.

The Company emphasizes a global market layout and maximize the value of the projects by launching clinical studies and product registration simultaneously in China and US. The sales scale of the series of products can be up to tens of billions RMB after they are on the market. The Company's product pipeline covers two application pathways, i.e., 505(b)(1) and 505(b)(2), with a total of nearly 10 new drug products. The Company has held a pre-NDA meeting with US FDA for its first project, QP001, and has reached several agreements.